So let's keep it simple, the days of GNBT "high priority" NASDAQ listing have failed !! The "hope" of Nasdaq funding completely failed instead OTC toxic funding, major dilution, lawsuits ,SEC delays and lack of funding have caused many more delays including vaccine development. Because the inability to successfully list GNBT the company is trying to expedite NGIO spin off ......again it appears struggling to meet SEC requirements or support. A solid company structure, leadership and potential succes will attract reasonable funding regardless of OTC status !! ......it appears company credibility remains an ongoing issue ! Dawson James has raised plenty for others ......,...
No support No successful listing and even if NGIO is listed it raises concerns if current leadership will make the right decisions to move forward. ...............
Potential billions .....really?? Can't even update shareholders on current status .....including AE37/MERCK, REVENUES, ALTUCELL, Q2, VALUATION etc.
2019 should have been the year to get listed......what's the real problem !!
We have heard all the excuses........ the "incomplete" vaccines are leading the way to "complete" the mission .............what's next ......

https://www.globenewswire.com/news-release/20...sting.html

https://dawsonjames.com/transactions/